Zhi Tong Cai Jing·2026-01-08 13:50Group 1 - The core issue is the severe shortage of the antiviral drug Oseltamivir (Tamiflu) in the U.S. and globally, particularly in cold regions facing high flu activity [1][2][4] - The American Society of Health-System Pharmacists (ASHP) reported that the demand for Tamiflu has surged, with hospital visits for flu-like symptoms reaching the highest level in over 20 years [1][4] - The shortage of Oseltamivir is compared to the scarcity of DDR memory chips, indicating a critical supply-demand mismatch in the pharmaceutical sector [1][2] Group 2 - CVS Health reported a significant increase in demand for Oseltamivir, although it stated that there is not a widespread shortage across the U.S., with some areas experiencing more severe shortages than others [3] - The flu season has been exacerbated by a new variant of the flu virus, known as subclade K, which has led to a notable increase in hospital visits due to flu symptoms [4][5] - The Centers for Disease Control and Prevention (CDC) noted that only 43% of Americans have received the antiviral vaccine, contributing to the severity of the current flu season [4][6] Group 3 - Oseltamivir is classified as a neuraminidase inhibitor, effective in treating Influenza A and B, and is most effective when administered within 48 hours of symptom onset [5][6] - The FDA has approved Oseltamivir for use in individuals aged 2 weeks and older, with an emphasis on early treatment for high-risk populations [6] - Other antiviral medications listed by the CDC include Zanamivir, Peramivir, and Baloxavir, each with different mechanisms of action [6]